Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) Demonstrates Safety, Low Systemic Exposure, and No Anesthetic Effect in Healthy Participants

PURPOSE: This first-in-human (FIH) study evaluated the safety, tolerability, pharmacokinetics, and effect on corneal sensitivity of topical ocular SAF312 in healthy participants. METHODS: This double-masked, randomized study comprised single-ascending dose (SAD), multiple-ascending dose (MAD), and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Stasi, Kalliopi, Alshare, Qusai, Jain, Monish, Wald, Michael, Li, Yifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Cornea & External Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684620/
https://www.ncbi.nlm.nih.gov/pubmed/36394843
http://dx.doi.org/10.1167/tvst.11.11.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684620/
https://www.ncbi.nlm.nih.gov/pubmed/36394843
http://dx.doi.org/10.1167/tvst.11.11.15

Ejemplares similares